rs1169288 — HNF1A HNF1A Ile27Leu

Common coding variant in the HNF1A transcription factor dimerization domain that modestly reduces beta-cell function and transactivation activity, raising LDL cholesterol and lowering CRP, while increasing type 2 diabetes risk in normal-weight individuals and accelerating diabetes onset in MODY3 carriers

See your personal result for HNF1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HNF1A Ile27Leu — The Transcription Factor Tweak Linking Beta-Cell Function, LDL, and CRP

Your liver and pancreas run largely on a transcription factor called hepatocyte nuclear factor 1-alpha (HNF1A)11 hepatocyte nuclear factor 1-alpha (HNF1A)
HNF1A binds DNA as a homodimer and directly activates dozens of genes involved in glucose metabolism, lipoprotein production, and the acute-phase response; pathogenic HNF1A mutations cause MODY3, the most common monogenic diabetes. The rs1169288 variant introduces an isoleucine-to-leucine substitution at codon 27 (p.Ile27Leu, c.79A>C) — a subtle amino acid swap in HNF1A's dimerization domain that carries measurable metabolic consequences across the full spectrum from common polygenic diabetes risk to modifying the onset age of rare monogenic MODY3.

The Mechanism

Position 27 of HNF1A sits within its N-terminal dimerization domain22 dimerization domain
HNF1A must form a dimer to bind DNA efficiently; the dimerization domain mediates protein-protein contact that stabilizes the transcription complex at target gene promoters. The Leucine-27 substitution (C allele) measurably reduces HNF1A transcriptional activity on target promoters including GLUT2 (glucose transporter 2) and albumin in experimental cell models — a finding replicated across multiple expression systems. Because HNF1A directly activates the CRP promoter, the Leu allele is associated with moderately lower basal C-reactive protein levels. Simultaneously, HNF1A regulates hepatic lipoprotein metabolism, and partial loss of function shifts the lipid phenotype toward higher LDL cholesterol and apolipoprotein B — even though CRP falls. This paradoxical combination (lower inflammation marker, higher LDL) has been replicated in multiple large population studies and is a hallmark of the rs1169288C haplotype.

The Evidence

The largest single-study characterization of this variant's metabolic footprint comes from Reiner et al. 200933 Reiner et al. 2009
community-based European-American adults from CARDIA (n=2,890 younger adults) and CHS (n=3,680 older adults); two fully independent replication datasets. The C allele was associated with 0.10–0.15 SD units lower CRP and GGT, but concurrently higher LDL cholesterol, apolipoprotein B, creatinine, and fibrinogen — a profile consistent with partial HNF1A hypofunction in hepatic CRP suppression versus lipoprotein synthesis.

For type 2 diabetes, the weight-dependency finding by Yamada et al. 201444 Yamada et al. 2014
861 Japanese subjects (300 T2D, 561 controls); I27L was an independent determinant of beta-cell function in normal-weight individuals, measured by HOMA-β clarifies the earlier inconsistent literature: I27L increases T2D risk specifically in lean individuals, where genetic beta-cell dysfunction is not masked by obesity-driven insulin resistance. In overweight and obese individuals, the HNF1A signal is overwhelmed by weight-related metabolic noise.

The most clinically striking finding involves MODY3: Bacon et al. 201855 Bacon et al. 2018
meta-analysis of 781 HNF1A-MODY patients from UK and Norwegian national cohorts; stratified by mutation type (protein-truncating vs missense) showed that each Leu-27 allele reduced age at diabetes diagnosis by 1.6 years (95% CI −2.6 to −0.7) in the subset with protein-truncating HNF1A mutations. The biological interpretation is clear: the I27L polymorphism already partially impairs the same transcriptional pathway that pathogenic HNF1A mutations devastate; stacking a mild common variant onto a severe rare variant advances disease onset by years.

An unexpected pharmacogenomics application was reported by Cecchin et al. 201766 Cecchin et al. 2017
two independent cohorts of metastatic colorectal cancer patients treated with FOLFIRI; total n=160 discovery + 82 replication: the rs1169288C allele (Leu-27) was associated with 45% higher irinotecan drug exposure and significantly improved progression-free survival. The mechanism involves HNF1A-driven regulation of ABCC2, an irinotecan efflux transporter — the Leu allele reduces ABCC2 expression, allowing more drug to remain in tumor tissue.

Practical Implications

For most C-allele carriers, the key actionable signal is the LDL elevation. Monitoring fasting LDL alongside standard diabetes screening captures both the lipid and glycemic dimensions of this variant's risk profile. In lean individuals, the diabetes risk is particularly relevant because the variant exerts its effect through beta-cell transcriptional insufficiency, which can be partly compensated by reducing carbohydrate-driven insulin demand.

The lower CRP associated with Leu-27 should not be interpreted as cardiovascular protection — it reflects reduced hepatic acute-phase expression, not reduced vascular inflammation. The LDL elevation tells the more complete cardiometabolic story.

Interactions

The rs1169288 C allele is in strong linkage disequilibrium (r² > 0.8, D' > 0.8) with rs2464196 (HNF1A Ser487Asn)77 rs2464196 (HNF1A Ser487Asn)
A second common coding variant at the 3' end of HNF1A at codon 487; S487N may have partially independent effects on HNF1A C-terminal transactivation domain function and with the intronic rs2244608. These variants form a common haplotype with a combined frequency of ~30% in Europeans. Because they travel together, published associations with CRP, LDL, and diabetes risk likely reflect the cumulative effect of the whole haplotype rather than Ile27Leu alone.

For individuals carrying pathogenic HNF1A mutations (MODY3 families), the I27L status modifies diagnosis age — a compound interaction between this common variant and rare HNF1A mutations that is now clinically documented. Genetic counselors and MODY clinics should consider rs1169288 genotyping as a modifier when advising MODY3 families about expected disease trajectory.

Genotype Interpretations

What each possible genotype means for this variant.

AA HNF1A Ile/Ile Normal

Common genotype with full HNF1A transactivation activity and standard metabolic baseline

The Ile/Ile (AA) genotype represents full HNF1A dimerization domain integrity. In cell models, Ile-27 maintains near-complete transcriptional activation of HNF1A target promoters compared to the Leu variant. Population data from CARDIA and CHS (Reiner et al. 2009) showed that AA individuals have higher basal CRP and GGT (reflecting intact HNF1A-driven hepatic acute-phase gene expression) but comparatively lower LDL, ApoB, and fibrinogen than C-allele carriers. This pattern is consistent with HNF1A's dual role: activating the CRP promoter (a hepatic acute-phase gene) while suppressing hepatic lipoprotein overproduction.

In the context of MODY3 families, Ile/Ile homozygotes with protein- truncating HNF1A mutations do not receive an additive modifier effect from this locus — they carry the severe mutation at the same dosage but without the mild common-variant amplification.

AC HNF1A Ile/Leu Intermediate

One copy of the Leu-27 allele modestly reduces HNF1A activity, raising LDL and lowering CRP

The Ile/Leu (AC) genotype shows intermediate HNF1A transactivation activity between the AA and CC states. In the CARDIA/CHS community- based cohorts (n=6,570 European-Americans across two independent studies), heterozygous carriers showed approximately 0.10–0.12 SD units lower CRP and GGT and modestly higher LDL cholesterol and apolipoprotein B compared to AA individuals. These effects are additive — each Leu allele contributes a similar increment.

The T2D risk signal for AC individuals is present but attenuated compared to CC homozygotes. Yamada et al. (2014) found that the I27L variant reduced HOMA-β (beta-cell function index) as a continuous trait across all genotypes in normal-weight subjects, with each C allele adding incremental impairment. In lean AC individuals with additional diabetes risk factors (family history, sedentary lifestyle, or impaired fasting glucose), the HNF1A partial hypofunction is clinically meaningful.

For MODY3 heterozygotes who also carry the I27L polymorphism in AC form, the 1.6-year acceleration per Leu allele (Bacon et al. 2018) predicts approximately 1.6 years earlier diabetes diagnosis on average relative to II homozygotes with the same HNF1A pathogenic mutation.

CC HNF1A Leu/Leu High Risk

Two copies of Leu-27 produce the strongest HNF1A hypofunction signal — elevated LDL, lower beta-cell reserve, and meaningful T2D risk in lean individuals

The CC homozygote doubles the Ile27Leu dose. In the key functional study, Leu/Leu (CC) combinations produced the greatest reduction in HNF1A transcriptional activation of GLUT2 and albumin promoters compared to all other genotype combinations. Population studies confirm the additive dose-response pattern: CC individuals show the lowest CRP, the highest LDL cholesterol, and the most suppressed HOMA-β (beta-cell function) in normal-weight cohorts.

In the Yamada et al. (2014) Japanese cohort, Leu/Leu homozygotes showed the highest insulin resistance (HOMA-IR) and the lowest beta-cell insulin secretion index in normal-weight subjects — the combination that puts a person on the most direct path to type 2 diabetes through insufficient compensatory insulin secretion rather than primary insulin resistance.

In the Bacon et al. (2018) MODY3 meta-analysis, carrying two Leu alleles was associated with diagnosis approximately 3.2 years earlier than Ile/Ile homozygotes with the same protein-truncating HNF1A mutation (extrapolated from the additive 1.6 years per allele estimate). This is not a small effect in a disease where earlier diagnosis substantially changes clinical management.

The irinotecan pharmacogenomics angle (Cecchin et al. 2017) applies maximally to CC carriers: the rs1169288C allele reduces hepatic ABCC2 (an irinotecan efflux transporter) expression, with CC homozygotes showing the greatest irinotecan drug exposure and best progression-free survival in metastatic colorectal cancer treated with FOLFIRI regimens. This is a favorable pharmacogenomic interaction in the cancer treatment context but indicates a potentially meaningful drug-gene interaction with other ABCC2 substrates.